Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )

Nivolumab shows early promise in Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA

Nivolumab shows early promise in Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )

Blinatumomab demonstrates significant clinical activity in residual ALL

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

Blinatumomab demonstrates significant clinical activity in residual ALL ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

New immunotherapy compound effective, safe in ALL patients with minimal...

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

New immunotherapy compound effective, safe in ALL patients with minimal residual disease ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

T cell therapy leading to prolonged remission for children with aggressive...

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

T cell therapy leading to prolonged remission for children with aggressive leukaemia ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

ASH 2014: Expert discussion on the latest in AML

Prof Alan Burnett and Prof Sergio Amadori

ASH 2014: Expert discussion on the latest in AML ( Prof Alan Burnett and Prof Sergio Amadori )

Immunology highlights from ASH 2014

Dr Catherine Bollard - George Washington University, Washington, USA

Immunology highlights from ASH 2014 ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: Blinatumomab for acute lymphocytic leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: Blinatumomab for acute lymphocytic leukaemia ( Dr Catherine Bollard - George Washington University, Washington, USA )

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

Dr Catherine Bollard - George Washington University, Washington, USA

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma ( Dr Catherine Bollard - George Washington University, Washington, USA )

ASH 2014: Expert discussion on the latest in CLL

Prof John Gribben and Prof Stephan Stilgenbauer

ASH 2014: Expert discussion on the latest in CLL ( Prof John Gribben and Prof Stephan Stilgenbauer )

Engineering stem cell resistance to HIV for two-pronged approach to HIV...

Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma ( Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA )

More from ecancer